Original sentence: A 2019 editorial in The BMJ called post finasteride syndrome "ill defined and controversial".A lack of clear diagnostic criteria and the variable reporting fraction in different health-care settings make the problem challenging to evaluate.In 2019 Reuters reported that faulty redactions in court documents revealed allegations from plaintiffs that Merck had known of persistent side effects in their original clinical trials but chose not to disclose them in warning labels.Other scientists have suggested post-finasteride syndrome is a delusion or psychotic disorder, akin to other conditions such as Morgellons syndrome or multiple chemical sensitivity.Post-finasteride syndrome describes a range of sexual, physical and neurological side effects that are reported to persist and develop after cessation of finasteride or dutasteride use.Preclinical evidence demonstrates interference by 5alpha-reductase inhibitors in sexual, cognitive and physical domains relevant to reported persistent symptoms.The existence of the condition is often considered controversial, owing to both the underlying biological mechanism and the incidence of the condition being unclear
Edited sentence: A 2019 editorial in The BMJ described post finasteride syndrome as an "ill defined and controversial associated with a constellation of sexual, physical, and psychological symptoms that develop during or after finasteride exposure and persist after discontinuation".A 2020 JAMA Dermatology editorial drew attention to the fact that reporting of sexual adverse events had been reporting in the original label, little attention was paid when Merck updated their product label in 2002 and removed the word "all" by changing the language from “resolution occurred in all men who discontinued therapy” to “resolution occurred in men who discontinued therapy.A presentation was given at the American Urological Association (AUA) to discuss the controversies surrounding post-finasteride syndrome and offered summaries of data from the FDA Adverse Events Reporting System (FAERS).Although the incidence and biological mechanisms of post-finasteride syndrome are unknown, it is known that 5α-reductase inhibitors reduce synthesis of brain neurosteroids, which affect mood, cognition, and libido.Court Let Merck Hide Secrets About Popular Drug's Risks which sealed court documents revealed allegations from plaintiffs' lawyers that Merck had known of persistent side effects in their original trials but chose not to disclose them in warning labels.Other doctors published an article stating in their opinion that post-finasteride syndrome demonstrates some analogies to controversial mystery syndromes such as amalgalm illness, Morgellons syndrome, multiple chemical sensitivity, and koro.Since 2008, at least 17 countries including the US and UK have warned prescribers of the possibility of the potential for finasteride to cause depression or sexual side effects.The authors concluded that the existence of PFS "is not discernable within this context and database".”  This label change was first widely reported in a 2019 Reuters investigation "U